北京祥瑞生物制品有限公司

Beijing Sanroad Biological Products Co. , Ltd. is located in the "mountain and clear water show, elegant environment", enjoy the Beijing "back garden" called Beijing Huairou Science City. Sanroad Bio was founded in 2000, registered capital of 114 million yuan, covers an area of 40 acres, is an innovation-driven high-tech enterprises. The company adheres to the vision of "making health simpler", bearing in mind the mission of "providing more effective products and services for health", integrates research and development, production and sale of biological products, biologics, chemicals, in vivo and in vitro diagnostic reagents, and comprehensively builds integrated solutions in the field of tuberculosis and introduces innovative vaccines overseas to jointly develop the Chinese market. The company currently has independent research and development of biological products for prevention "A, C group meningococcal conjugate vaccine (patented products)" - "NAOMANNING®", the product in February 2011 to obtain "new drug certificate", "drug registration approval." The "NAOMANNING®" is a new generation of fluid-combined vaccine signed against group B meningococcal infection, which sets a precedent for the application of a combination vaccine with the same pathogenic bacteria and different serum groups (types) as protein carriers. In the Sanroad product sequence, by China's independent research and development, included in the national pharmacopeia standard reference products, "TB-PPD" is the national 2018 version of the basic drug catalog, Class A health insurance drugs. "TB-PPD 50IU/ml.1 ml/branch)" is used for diagnosis and differential diagnosis of clinically suspected patients, and for high-risk population identification. "TB-PPD 20IU/ml.1 ml/branch)" is dedicated to epidemiological investigation of tuberculosis, student TB screening and health check-ups. "Caxamcine pure protein derivatives (BCG-PPD 50IU/ml.1 ml/branch)" are mainly used for the evaluation of the immune effect after vaccination of caedes. At present, our company is the main domestic production enterprises of the three products, products all over the country 31 provinces, municipalities and autonomous regions, covering most of the country's cities and more than 80 percent of the rural areas, forming a broad and stable sales network. Sanroad Bio has an independent research and development institutions (research institutes), research and development capabilities are strong, in the research projects by the national and Beijing project support. Sanroad Bio will adhere to the research and development-driven strategy, play the core technology advantages, for health continuous exploration, continuous innovation!